23.80EUR-2.70%Mkt Cap: —P/E: 3.21Last update: 2026-06-01
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value-1.36B EUR
Revenue (TTM)1.04B EUR
Gross Profit1.08B EUR
Net Income (TTM)320.88M EUR
Revenue/Share15.84 EUR
Last Price23.80 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINBE0003818359
Valuation
P/E (Trailing)3.21
P/E (Forward)-6.85
PEG—
EV/EBITDA-2.06
EV/Revenue-1.31
P/S—
P/B—
EPS (TTM)7.41
EPS (Forward)-3.57
52W Range
22.6212% of range32.74
52W High32.74 EUR
52W Low22.62 EUR
Profitability
Gross Margin97.33%
Oper. Margin-982.92%
EBITDA Margin63.52%
Profit Margin28.85%
ROE9.92%
ROA9.42%
Growth
Revenue Growth-91.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-257.46M EUR
CapEx (TTM)13.86M EUR
FCF Margin20.21%
FCF Yield—
Net Debt-2.98B EUR
Net Debt/EBITDA-4.49
Balance Sheet
Debt/Equity0.00
Current Ratio30.48
Quick Ratio30.23
Book Value/Sh—
Cash/Share45.26 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.4 (Hold)
Target (Mean)30.15 EUR
Target Range19.00 EUR – 44.80 EUR
# Analysts8
Ownership
Shares Out.—
Float44.54M
Insiders25.36%
Institutions32.42%
Technical
SMA 5024.62 (-3.3%)
SMA 20027.18 (-12.4%)
Beta0.12
S&P 52W Chg27.94%
Avg Vol (30d)65.56K
Avg Vol (10d)56.29K
Technical Indicators
RSI (14)53.8
MACD-0.1736
MACD Signal-0.3498
MACD Hist.+0.1762
BB Upper24.75 EUR
BB Middle23.82 EUR
BB Lower22.90 EUR
BB Width7.75%
ATR (14)0.6222 EUR
Vol Ratio (20d)1.95x